ALDX Live signals | Maximize Profits with Getagraph.com

BUY 102365 min ago

@ $3.36

Issued: 14 Feb 2024 @ 13:54

Return: 17.44%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 4.19 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	460 523
Average Volume	589 485
Market Cap	234.09M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.0800 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.16
ATR14	$0.00700 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Machatha Stephen	Sell	11 537	Common Stock
2024-03-11	Greenberg Bruce	Sell	13 201	Common Stock
2024-04-05	Perceptive Advisors Llc	Buy	37 712	Common Stock
2024-04-04	Perceptive Advisors Llc	Buy	140 281	Common Stock
2024-04-03	Perceptive Advisors Llc	Buy	309 847	Common Stock

INSIDER POWER
17.61
Last 100 transactions
Buy: 8 132 048 \| Sell: 3 580 213

Volume Correlation

Long: 0.09 (neutral)

Short: 0.59 (weak)

Signal:(55.796) Neutral

Aldeyra Therapeutics Inc Correlation

10 Most Positive Correlations
SVVC	0.96
BOCH	0.96
ACCD	0.956
VORB	0.955
AEZS	0.955
VIAV	0.955
PHCF	0.954
LMDX	0.954
NEOG	0.952
CTHR	0.952

10 Most Negative Correlations
ORTX	-0.975
DLHC	-0.959
ISTR	-0.957
RETA	-0.953
THRN	-0.953
ESSA	-0.949
FRBK	-0.948
FMIV	-0.946
INO	-0.945
DAWN	-0.944

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aldeyra Therapeutics Inc Correlation - Currency/Commodity

0.27
( neutral )

0.32
( neutral )

0.00
( neutral )

-0.44
( neutral )

0.04
( neutral )

Aldeyra Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-262 780 (0.00 %)
EPS:	$-0.640

Q4	2023
Revenue:	$392 620
Gross Profit:	$326 151 (83.07 %)
EPS:	$-0.0803

Q3	2023
Revenue:	$0
Gross Profit:	$-64 999.00 (0.00 %)
EPS:	$-0.140

Q2	2023
Revenue:	$0
Gross Profit:	$-64 339.00 (0.00 %)
EPS:	$-0.150

Financial Reports:

No articles found.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.